Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors

Background and Objectives: The aim of this study is to investigate the characteristics of gastrointestinal bleeding events associated with BCR-ABL tyrosine kinase inhibitor (TKI) treatment, using the reporting odds ratio (ROR) of the adverse event reports submitted to the Japanese Adverse Drug Event Report database between 2004 and 2020, and to examine the number of reported TKI-related gastrointestinal bleeding cases according to sex and age, as well as the actual number of TKI prescriptions issued in Japan. Materials and Methods: The RORs and 95% confidence intervals (CIs) of gastrointestinal bleeding events related to TKIs were calculated using the data of the 595,121 included cases. Results: Significant gastrointestinal bleeding events were detected for dasatinib (crude ROR: 4.47, 95% CI: 3.77–5.28) and imatinib (crude ROR: 1.22, 95% CI: 1.01–1.46). In multiple logistic regression analyses, significant gastrointestinal bleeding events were detected for dasatinib (adjusted ROR: 8.02, 95% CI: 5.75–10.2), imatinib (adjusted ROR: 1.81, 95% CI: 1.2–2.72), age (≥60 years, adjusted ROR: 2.22, 95% CI: 2.1–2.36), reporting year (adjusted ROR: 1.04, 95% CI: 1.04–1.05), and male sex (adjusted ROR: 1.47, 95% CI: 1.37–1.57). Interaction analysis revealed that the association of gastrointestinal bleeding with dasatinib was affected by age (≥60 years) and sex (female), with the number and proportion of dasatinib-related gastrointestinal bleeding cases increasing among those aged ≥60 years. Conclusions: Specific TKIs and patient characteristics were associated with gastrointestinal bleeding. Our results aid the prompt identification and treatment of TKI-related gastrointestinal bleeding.

[1]  Cassie S. Mitchell,et al.  Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia , 2021, Cancers.

[2]  T. Ishida,et al.  Risk Factors for Pseudoaldosteronism with Yokukansan Use: Analysis Using the Japanese Adverse Drug Report (JADER) Database. , 2020, Biological & pharmaceutical bulletin.

[3]  Y. Kinosada,et al.  Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database , 2019, International journal of medical sciences.

[4]  R. Saxena,et al.  Imatinib-induced platelet dysfunction and hypofibrinogenemia in chronic myeloid leukemia. , 2019, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[5]  Á. Illés,et al.  Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia , 2018, Platelets.

[6]  Y. Kinosada,et al.  Evaluation of Drug-Induced Photosensitivity Using the Japanese Adverse Drug Event Report (JADER) Database. , 2017, Biological & pharmaceutical bulletin.

[7]  S. Mustjoki,et al.  Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner , 2017, Clinical Cancer Research.

[8]  S. Kimura,et al.  Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg , 2017, Clinical lymphoma, myeloma & leukemia.

[9]  G. Bar-Sela,et al.  Imatinib-induced Gastrointestinal Vascular Ectasia in a Patient with Advanced GIST: Case Report and Literature Review. , 2016, Anticancer research.

[10]  H. Prince,et al.  Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report , 2015, Platelets.

[11]  Y. Kinosada,et al.  Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. , 2015, Biological & pharmaceutical bulletin.

[12]  M. Molokhia,et al.  Illustration of the Weibull Shape Parameter Signal Detection Tool Using Electronic Healthcare Record Data , 2013, Drug Safety.

[13]  M. Baccarani,et al.  Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). , 2012, Blood.

[14]  R. Latagliata,et al.  "Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. , 2010, Leukemia research.

[15]  P. Ding,et al.  BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. , 2010, Leukemia research.

[16]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[17]  C. Récher,et al.  The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. , 2009, Blood.

[18]  H. Kantarjian,et al.  Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. , 2009, Blood.

[19]  H. Kantarjian,et al.  Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy , 2009, Cancer.

[20]  M. Cameron,et al.  Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways , 2009, Drug Metabolism and Disposition.

[21]  Ulrich Klotz,et al.  Pharmacokinetics and drug metabolism in the elderly , 2009, Drug metabolism reviews.

[22]  P. Nürnberg,et al.  Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. , 2007, Pharmacogenomics.

[23]  M. Baccarani,et al.  Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. , 2007, Haematologica.

[24]  Kenneth J Rothman,et al.  The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.

[25]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[26]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.